drugset
drugset / Trial / NCT03805503

Chloroprocaine for Inguinal Herniorrhaphy

NCT03805503 ↗

Phase 4 Completed 12 enrolled University Hospital, Ghent
SequentialOpen-labelTreatment

Summary

This study is to determine the minimum effective dose for intrathecal chloroprocaine in inguinal herniorrhaphy in outpatients using a Combined Spinal Epidural (CSE) anesthesia.

Timeline

Start
2015-09-16
Primary completion
2017-09-07
Completion
2018-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Chloroprocaine Other / unclassified 5 ml Intrathecal
Subject Chloroprocaine Other / unclassified 50 mg Intrathecal

Indications

No indication recorded.